Phathom Pharmaceuticals Inc
NASDAQ:PHAT

Watchlist Manager
Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Watchlist
Price: 13.55 USD -4.51% Market Closed
Market Cap: $963.9m

Net Margin

-186.5%
Current
Improving
by 5 420.7%
vs 3-y average of -5 607.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-186.5%
=
Net Income
$-274.6m
/
Revenue
$147.2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-186.5%
=
Net Income
$-274.6m
/
Revenue
$147.2m

Peer Comparison

Country Company Market Cap Net
Margin
US
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
980.4m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Lower than 88% of companies in the United States of America
Percentile
12th
Based on 15 072 companies
12th percentile
-186.5%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Phathom Pharmaceuticals Inc
Glance View

Market Cap
963.9m USD
Industry
Pharmaceuticals

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

PHAT Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-186.5%
=
Net Income
$-274.6m
/
Revenue
$147.2m
What is Phathom Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Phathom Pharmaceuticals Inc is -186.5%, which is above its 3-year median of -5 607.3%.

How has Net Margin changed over time?

Over the last 2 years, Phathom Pharmaceuticals Inc’s Net Margin has increased from -29 558.9% to -186.5%. During this period, it reached a low of -29 558.9% on Dec 31, 2023 and a high of -186.5% on Sep 30, 2025.

Back to Top